ARTICLE | Emerging Company Profile
Deliver to the liver
How Topas is using the liver to induce systemic autoantigen tolerance
May 9, 2016 7:00 AM UTC
Topas Therapeutics GmbH is turning a shortcoming of nanoparticles - difficulty escaping the liver - into an advantage. The company is targeting a subset of liver cells that are among the most tolerizing in the body as part of a platform that could induce antigen-specific immune tolerance more potently than competing technologies.
The newco initially is targeting multiple sclerosis and plans to apply its technology to a host of other autoimmune diseases where causal antigens are known and characterized...